This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsigos, C. Articles by Papanicolaou, D. A. Search for Related Content PubMed PubMed Citation Articles by Tsigos, C. Articles by Papanicolaou, D. A.

Prolonged Suppression of Corticosteroid-Binding Globulin by Recombinant Human Interleukin-6 in Man

Hellenic National Diabetes Center Athens, Greece

George P. Chrousos and Dimitris A. Papanicolaou

Developmental Endocrinology Branch National Institute of Child Health and Human Development, NIH Bethesda, Maryland

Corticosteroid-binding globulin (CBG), a glucoprotein of hepatic origin, binds cortisol and modifies its bioavailability (1). Interleukin-6 (IL-6) dose-dependently inhibits CBG messenger RNA expression and protein secretion by hepatoblastoma-derived (HepG2) cells (2). This is consistent with the presence of a nuclear factor-IL-6-binding site in the rat CBG gene promoter, also conserved in the promoter of the human CBG gene (3). These findings suggest that CBG is a negative acute phase reactant protein.

We recently reported the results of a dose-response study of single subcutaneous injections of recombinant human IL-6 on pituitary hormone production and glucose metabolism in healthy male volunteers (4, 5). We hereby provide evidence from these volunteers that supports the inhibitory effect of IL-6 on CBG production. We measured CBG (6), cortisol, and the positive acute phase reactant C-reactive protein (CRP) at baseline, then at 24 h, 48 h, and 7 days after the IL-6 injection in three volunteers who received 0.3 µg/kg of IL-6, a dose that did not activate the hypothalamic-pituitary-adrenal (HPA) axis and in three volunteers who received 3.0 µg/kg of IL-6, a dose that strongly stimulated the HPA axis (4).

Plasma IL-6 levels reached a peak of 22 ± 5 pg/mL and 290 ± 38 pg/mL for the two doses respectively, between 2 and 4 h after the injection, and returned to baseline by 24 h in both groups. While the 0.3 µg/kg dose did not appreciably influence plasma CBC levels, the 3.0 µg/kg dose caused a significant and persistent decrease in CBC levels that lasted at least 48 h, but returned to baseline by 7 days (Fig. 1).The corresponding CRP levels showed a mirror image response, increasing significantly by 24 h (from 0.77 ± 0.06 mg/dL to 9.8 ± 1.01 mg/dL, P < 0.01), remaining elevated at 48 h (6.0 ± 1.24, P < 0.05 vs. baseline) and returning to normal by 7 days (0.75 ± 0.05 mg/dL). Cortisol levels, despite the dramatic response observed during the first 4 h after the IL-6 injection (4), were at baseline by 24 h and remained so thereafter.

View larger version (14K): [in this window] [in a new window]   Figure 1. Mean ± SE plasma CBG responses to the two doses (0.3 and 3.0 µg/kg) of recombinant human IL-6 administration. * P < 0.02 by paired t-test.

Footnotes

Address correspondence to: Constantine Tsigos, M.D., Hellenic National Diabetes Center, 3 Ploutarchou Street, 106 75 Athens, Greece.

Received April 23, 1998.

References

1. Rosner W. 1990 The functions of corticosteroid-binding globulin and sex-hormone binding globulin: recent advances. Endocr Rev. 11:80–91.[Abstract/Free Full Text]
2. Emptoz-Bonneton A, Crave JC, Lejeune H, Brebart C, Pugeat M. 1997 Corticosteroid-binding globulin synthesis regulation by cytokines and glucocorticoids in human hepatoblastoma-derived (HepG2) cells. J Clin Endocrinol Metab. 82:3758–3762.[Abstract/Free Full Text]
3. Underhill DA, Hammond GL. 1995 cis-Regulatory elements within the proximal promoter of the rat gene encoding corticosteroid-binding globulin. Gene. 162:205–211.[CrossRef][Medline]
4. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP. 1997 Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab. 82:4167–4170.[Abstract/Free Full Text]
5. Tsigos C, Papanicolaou DA, Defensor R, Mitsiadis CS, Kyrou I, Chrousos GP. 1997 Dose-effects of recombinant human interleukin-6 on anterior pituitary hormone secretion and thermogenesis. Neuroendocrinology. 66:54–62.[Medline]
6. Pugeat MM, Nisula BC, Dunn JF. 1981 Transport of steroid hormones: interaction of 70 drugs with testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab. 53:69–75.[Abstract/Free Full Text]
7. Baigrie RJ, Lamont PM, Kwiatkowski D, Dallman MJ, Morris PJ. 1992 Systemic cytokine response after major surgery. Br J Surg. 79:759–760.
8. Evans SW, Whicher JT. 1993 The cytokines: physiological and pathophysiologic aspects. Adv Clin Chem. 30:1–88.[Medline]

This article has been cited by other articles:

				K. Wingenfeld, C. Heim, I. Schmidt, D. Wagner, G. Meinlschmidt, and D. H. Hellhammer HPA Axis Reactivity and Lymphocyte Glucocorticoid Sensitivity in Fibromyalgia Syndrome and Chronic Pelvic Pain Psychosom Med, January 1, 2008; 70(1): 65 - 72. [Abstract] [Full Text] [PDF]

				J.-M. Fernandez-Real, M. Pugeat, M. Grasa, M. Broch, J. Vendrell, J. Brun, and W. Ricart Serum Corticosteroid-Binding Globulin Concentration and Insulin Resistance Syndrome: A Population Study J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4686 - 4690. [Abstract] [Full Text] [PDF]

				D. J. Torpy, A. W. Bachmann, J. E. Grice, S. P. Fitzgerald, P. J. Phillips, J. A. Whitworth, and R. V. Jackson Familial Corticosteroid-Binding Globulin Deficiency Due to a Novel Null Mutation: Association with Fatigue and Relative Hypotension J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3692 - 3700. [Abstract] [Full Text] [PDF]

				J.-M. Fernández-Real, M. Grasa, R. Casamitjana, M. Pugeat, C. Barret, and W. Ricart Plasma Total and Glycosylated Corticosteroid-Binding Globulin Levels Are Associated with Insulin Secretion J. Clin. Endocrinol. Metab., September 1, 1999; 84(9): 3192 - 3196. [Abstract] [Full Text]

This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsigos, C. Articles by Papanicolaou, D. A. Search for Related Content PubMed PubMed Citation Articles by Tsigos, C. Articles by Papanicolaou, D. A.